The global migraine drugs market had a valuation of USD 6.7 Billion in 2022 and is anticipated to reach USD 10.9 Billion by 2032, exhibiting a robust compound annual growth rate (CAGR) of 4.7% throughout the forecast period. Key drivers of market revenue growth include the increasing prevalence of migraine worldwide, enhanced awareness among patients and physicians regarding the importance of...
English
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά